|
Cyplasin™ therapeutic protein Cyplasin-SC™ is a glycoprotein derived from a marine organism known as the sea hare (Aplysia punctata). This protein is highly toxic for certain cancer cell types but in our invitro studies has been shown to have no effect on normal healthy human cells in concentrations that kill the tumor cells. Cyplasin-SC has been sequenced and plasmids coding for it have been generated and introduced into human cells. These human cells in culture produce the recombinant Cyplasin glycoprotein for our use. Different cancer types show different sensitivity to a given therapeutic treatment. In addition different patients with the same cancer type need different doses of therapeutics for an efficient treatment. While cells get killed at a low concentration in some patients others need twice the dose. One challenge in therapeutic development consists in optimising the required concentration for individual tumours without harming healthy cells. The concentration window of a drug candidate has to be large enough to meet individual needs and separated enough from a concentration that may harm normal cells. Cyplasin induces cell death in many types of autonomously growing transformed mammalian cells.(tumor cells) and the cytotoxic effect occurs irreversibly at nanomolar concentrations of Cyplasin. Under these conditions normal cells remain unharmed. Cyplasin-SC™ It is believed that Cyplasin-SC™ in general kills cancer cells by triggering a cell surface receptor causing the cell to kill itself. The data below demonstrates that Cyplasin is able to destroy the target skin cancer and melanoma tumor cells.
The graph above shows how Cyplasin does not affect normal healthy cells. HUVEC (normal human primary cells) maintain metabolic activity after exposure to Cyplasin. When exposed to Cyplasin-SC for 24 hours, the HUVEC cells show 100% metabolic activity, demonstrating no cytotoxicity of Cyplasin-SC with these cells.
This graph shows cell death for melanoma after exposure to Cyplasin-SC. Cyplasin used at concentrations of 60 nM and 30 nM kills at least an 80% of melanoma cells. These cells are highly sensitive to Cyplasin. Cyplasin-SC may be formulated to be administered via microinjection close to the skin tumor or intradermally (under the skin). Please contact us to request more information about Cyplasin-SC. |
|
Cell death for melanoma cells after exposure to Cyplasin-SC™. Cyplasin concentrations 60 nM and 30 nM kills at least 80% of melanoma cells. These cells are highly sensitive to cyplasin. |